Bill is a retired partner. He previously served as senior counsel in the Food & Drug practice and as a member of the Life Sciences industry team. He served as the firm’s managing partner from 1996–2008 and served as chairman of the Healthcare practice.
Bill’s practice focused on food and drug law and government investigations. He advised companies in the food, medical device, pharmaceutical, and biotech industries on a wide range of issues, including strategies for obtaining Food and Drug Administration (FDA) approvals of new products, clinical trials, risk management, advertising and labeling, good manufacturing practices, and post-approval safety requirements. He also counseled companies about recalls, market withdrawals, crisis management, responding to FDA inspectional observations and warning letters, the defense of anticipated enforcement actions, and the negotiation of consent decrees. He defended clients in both administrative hearings and enforcement actions in federal and state courts involving the FDA, Federal Trade Commission (FTC), Drug Enforcement Agency (DEA), Environmental Protection Agency (EPA), and the U.S. Department of Agriculture. He also performed regulatory due diligence for clients in connection with financings, public offerings, mergers and acquisitions, and assists with Securities and Exchange Commission (SEC) regulatory filings and press releases to the investment community.
Bill published numerous books and articles on food and drug law and regulatory law topics. He was an adjunct professor at Emory University School of Law, where he taught food and drug law for 40 years.